Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy - UTU Research Portal

A1 Refereed original research article in a scientific journal

Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy

Authors: Manceau G, Imbeaud S, Thiebaut R, Liebaert F, Fontaine K, Rousseau F, Genin B, Le Corre D, Didelot A, Vincent M, Bachet JB, Chibaudel B, Bouche O, Landi B, Bibeau F, Leroy K, Penault-Llorca F, Van Laethem JL, Demetter P, Tejpar S, Rossi S, Mosakhani N, Osterlund P, Ristamaki R, Sarhadi V, Knuutila S, Boige V, Andre T, Laurent-Puig P

Publisher: AMER ASSOC CANCER RESEARCH

Publication year: 2014

Journal: Clinical Cancer Research

Journal name in source: CLINICAL CANCER RESEARCH

Journal acronym: CLIN CANCER RES

Volume: 20

Issue: 12

First page : 3338

Last page: 3347

Number of pages: 10

ISSN: 1078-0432

DOI: https://doi.org/10.1158/1078-0432.CCR-13-2750

Abstract

Conclusion: Hsa-miR-31-3p seems to be a new mCRC biomarker whose expression level allows for the identification of patients with wild-type KRAS mCRC who are more likely to respond to anti-EGFR therapy. Clin Cancer Res; 20(12); 3338-47.(C) 2014 AACR.